Search filters

List of works by Katja Weisel

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

scientific article published on 08 November 2018

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens

scientific article published on 31 January 2017

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

scientific article

A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

scientific article published on 28 April 2016

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

scientific article published on 08 April 2019

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

scientific article published on 08 December 2011

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

scientific article

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

scientific article published on 14 April 2016

Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

scientific article published on 30 May 2020

Automated "Bone Subtraction" Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma

scientific article

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

scientific article published on 11 December 2017

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

scientific article published on 16 December 2019

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

scientific article

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

scientific article published on 29 June 2018

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

scientific article published on 20 July 2020

Can Whole-body Low-dose Multidetector CT Exclude the Presence of Myeloma Bone Disease in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)? ⬇️

scientific article published on January 1, 2012

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

scientific article

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

scientific article published on 22 October 2019

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

scientific article

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

scientific article published on 23 August 2017

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

scientific article published on 01 July 2020

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

scientific article published on 22 September 2017

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

scholarly article by Katharina Kriegsmann et al published 29 January 2019 in Blood Cancer Journal

Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.

scientific article published on 26 October 2013

Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma

scientific article published on 09 January 2020

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

scientific article published on 26 November 2015

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

article

Corrigendum to "Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography" [Eur. J. Radiol. 85 (December (12)), 2016, 2195-2199]

scientific article published on 03 May 2018

Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

scientific article published on 06 April 2020

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.

scientific article

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

scientific article published on 27 August 2019

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

scientific article

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

scientific article published on 10 March 2009

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

scientific article published on 01 May 2019

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

scholarly article by Andrew Spencer et al published 20 September 2018 in Haematologica

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

scientific article published on 09 October 2019

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

scientific article

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

scientific article published on 20 August 2020

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

scientific article published on 31 January 2020

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making

Differential effects of G protein coupled receptors on hematopoietic progenitor cell growth depend on their signaling capacities

scientific article published on 14 March 2007

Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma.

scientific article published in March 2015

Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results

scientific article published on July 2010

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

scientific article published on 01 November 2020

Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

scientific article published on 16 October 2020

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial

scientific article published on 11 September 2018

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

scientific article published on 04 September 2020

Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma

scientific article published on 7 October 2008

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.

scientific article published on 28 September 2008

Extended in vitro expansion of adult, mobilized CD34+ cells without significant cell senescence using a stromal cell coculture system with single cytokine support

scientific article

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

scientific article published on 17 November 2017

First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

scientific article published on 22 January 2020

Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.

scientific article published on 3 May 2017

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

scientific article published on 11 August 2016

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

scientific article published on 24 November 2020

Genetic and functional characterization of isolated stromal cell lines from the aorta-gonado-mesonephros region

scientific article

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

scientific article published on 16 December 2020

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

scientific article published on 25 November 2014

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

article

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

scientific article published on 24 September 2019

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

scientific article published on 09 April 2020

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

scientific article published on 11 March 2019

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

scientific article published on 28 February 2019

Imaging findings in relapsing multiple myeloma

scientific article published on 26 March 2009

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

scientific article

Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned

scientific article published in January 2016

Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm

scientific article published on 23 November 2016

Improvement of diagnostic confidence for detection of multiple myeloma involvement of the ribs by a new CT software generating rib unfolded images: Comparison with 5- and 1-mm axial images

scientific article published on 2 April 2015

Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.

scientific article published in January 2014

Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis

scientific article published on 24 June 2020

Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders

scientific article

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

scientific article published on 27 September 2019

Lenalidomide

scientific article published on January 2014

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

scientific article published on September 2014

Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment

scientific article published in July 2014

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

scientific article published on 07 January 2021

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

scientific article published on 11 May 2017

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

scientific article published on 11 March 2020

Maintenance and continuous therapy for multiple myeloma

scientific article published on 03 July 2018

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma ⬇️

scientific article published on 28 February 2020

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone

scientific article published in 2022

Modulation of CXC chemokine receptor expression and function in human neutrophils during aging in vitro suggests a role in their clearance from circulation

scientific article published on 15 April 2009

OP9 stroma augments survival of hematopoietic precursors and progenitors during hematopoietic differentiation from human embryonic stem cells

scientific article

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

scientific article published on 01 June 2018

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

scientific article published on 09 March 2020

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

scientific article published on 01 August 2019

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report

scientific article

Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease

scientific article published in September 2009

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

scientific article published on 18 August 2016

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

scientific article published on 2 February 2018

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

scientific article published on 6 June 2015

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

scientific article

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

scientific article

Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

scientific article published on 07 September 2020

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

scientific article published on 13 May 2019

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

scientific article published on 2 May 2018

Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.

scientific article

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

scientific article published on 26 June 2019

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

scientific article published on 26 September 2019

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla

scientific article

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

article

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

scientific article published on 19 August 2020

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).

scientific article

Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis

scientific article published on 11 November 2019

Response Assessment in Patients with Multiple Myeloma during Antiangiogenic Therapy using Arterial Spin Labeling and Diffusion-Weighted Imaging ⬇️

scientific article published on 01 November 2010

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

scientific article published on 07 February 2020

Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data

scientific article

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

scientific article

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

scientific article published on 21 July 2020

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

scientific article published on 17 February 2021

Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography

scientific article published on 17 October 2016

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date

scientific article

Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis

scientific article published on November 2006

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

scientific article published on 3 April 2015

Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion

scientific article published on 23 September 2014

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

scientific article published on 05 November 2018

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation

scientific article published on 10 May 2016

The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas

scientific article published on 2 May 2013

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy

scientific article

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

scholarly article by Mohamed H S Awwad et al published 2018 in OncoImmunology

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

scientific article published on 18 August 2011

Whole-Body Diffusion-Weighted MRI With Apparent Diffusion Coefficient Mapping for Early Response Monitoring in Multiple Myeloma: Preliminary Results ⬇️

scientific article published on 01 June 2011

Wnt1 overexpression leads to enforced cardiomyogenesis and inhibition of hematopoiesis in murine embryonic stem cells

scientific article

[Monoclonal Gammopathy Of Unknown Significance - A Common Incidental Finding - What is to be thought of? What has to be done?]

scientific article published on 16 July 2019

Paulina is supported by:

About Paulina

Help